CD274 and breast carcinoma: These include the PARP inhibitors olaparib and talazoparib for the treatment of germ-line BRCA gene mutation-associated breast cancer (gBRCAm-BC), and immunotherapy for advanced TNBC with programmed cell death ligand-1 positive (PD-L1+), Combined use of the checkpoint inhibitor atezolizumab with albumin-binding paclitaxel (Shen et al., 2020).